A1331853

A1331853 is a potent and selective small molecule inhibitor of BCL-XL (B-cell lymphoma-extra large), an anti-apoptotic member of the BCL-2 family. Developed by AbbVie, it is primarily utilized as a chemical probe in oncology research to investigate the role of BCL-XL in cell survival and to identify synergistic combinations with other agents, such as BCL-2 inhibitors (e.g., venetoclax). In preclinical studies, A1331853 has demonstrated the ability to sensitize various human blood cancer cell lines, including mantle cell lymphoma (MCL) and acute myeloid leukemia (AML), to apoptosis. It is particularly effective when combined with the depletion of other survival mediators like the mitochondrial E3 ligase MARCH5 or the inhibition of MCL1, suggesting its potential in overcoming resistance to standard BCL-2 targeted therapies.